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Abstract
Background: Endometrial cancer is the most common cancer of the female reproductive tract.
Based on our previous studies we speculated that miR-92a exhibited pro-oncogenic properties in endometrial
cancer, and therefore its inhibition could be used as a therapeutic measure in this disease. Therefore in the present
study we aimed to investigate both in vitro and in vivo if inhibition of miR-92a in endometrial cancer would limit
cancer cells proliferation.
Methods: miR-92a expression was evaluated in four endometrial cancer cell lines using qPCR. Inhibition of miR-92a
activity was obtained in endometrial cancer cell lines by a transient transfection of a custom designed Locked
Nucleic Acid (LNA)-Inhibitor, developed to work both in vitro and in vivo. In vitro proliferation studies were
performed using xCELLigence RTCA DP system. In vivo experiment was performed in Cby.Cg-Foxn1 < nu>/cmdb
mice bearing endometrial cancer xenografts, which were intraperitoneally injected with nine dosages of 25 mg/kg
of miR-205-LNA-inhibitor.
Results: qPCR revealed increased expression of miR-92a in HEC-1-B, Ishikawa and AN3CA cells. LNA-i-miR-92a inhibited
endometrial cancer growth in vitro. It was also demonstrated that systemic administration of LNA-i-miR-92a was
feasible and exerted inhibitory effect on endometrial cancer xenograft growth in vivo with only mild toxic effects in
treated animals, however the effect was observed until 12th experimental day and the last three dosages did not
maintain the attenuating effect with the acceleration of tumor growth observed at the end and after cessation of the
intraperitoneal therapy.
Conclusions: Taken together, these results indicate that intraperitoneal delivery of miR-92a-LNA-modified-inhibitor is
feasible, devoid of significant toxicity and moderately inhibits endometrial cancer growth in vivo, and therefore
warrants further studies investigating other routes of inhibitor delivery possibly in other animal models.
Keywords: miR-92a, LNA-inhibitor, Endometrial cancer, Mice xenograft, Proliferation, In vivo
Background
Endometrial cancer (EC) is a common and histologically
heterogeneous malignancy and although several molecu-
lar pathways were connected with its molecular basis
the pathogenesis of this malignancy has not been fully
elucidated [1]. Recently endometrial oncogenesis was
connected with alterations of microRNAs expression [2].
And a number of studies including our own research
reported microRNAs as promising diagnostic and prog-
nostic factors in EC [3–5].
MiR-92a, a member of miR-17-92 cluster, was re-
ported deregulated in several cancers being most com-
monly linked with gastrointestinal malignancies and
with colorectal carcinoma in particular [6, 7]. To our
best knowledge we were first to report its overexpression
both in tissues and in plasma of EC patients [3].
Based on those results and findings presented by other
authors indicating the possible role of miR-92a in
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PTEN/PI3K/Akt/mTOR, which is a canonical pathway
investigated in EC we hypothesized that miR-92a could
act as oncogene and promote carcinogenesis in endo-
metrial epithelium [8, 9].
Therefore in this study we aimed to investigate both in
vitro and in vivo if inhibition of miR-92a in EC would
limit cancer cells proliferation. Aiming at evaluation of
translational potential of miR-92a inhibition we chose
Locked Nucleic Acid (LNA)–inhibitor to induce the
knock–down of miR-92a. LNA–inhibitors were previ-
ously successfully applied in mice and non-human pri-
mates studies and proven to act after systemic delivery
[10, 11]. The miR-92a-LNA-inhibitor used in the pre-
sented study was custom designed to work both in vitro
and in vivo with the similar efficiency. To our knowledge
this is the first report to investigate in vitro and in vivo
effects of miR-92a inhibition in EC.
Methods
Tissues samples
Tissue samples of normal endometrium were obtained
from 31 patients operated due to benign gynecological
pathologies other than of endometrial origin. None of
the females enrolled in the control groups had a history
of cancer or endometrial pathology. Fresh tissue samples
(NE n = 16) were collected during the surgery within
15 min from the uterus removal and immediately
immersed in RNAlater (Thermo Fisher Scientific,
Waltham, MA, USA). After 24-h incubation in RNAlater
in 4 °C, tissues were stored in −80 °C until RNA extrac-
tion. FFPE tissues (n = 15) used for the study were fixed
with 10% formalin and stored for maximum 10 years.
Healthy endometrium included both proliferative and
secretory phase epithelium. There was no overlap be-
tween fresh and FFPE tissue samples Medical University
of Lublin Ethical Committee approved the study design
(# KE-0254/201/2008). Informed consent was obtained
from each study participant.
Cell lines
Endometrial carcinoma cell lines HEC-1-B, AN3CA and
KLE were purchased from ATCC (Manassas, VA, USA)
and Ishikawa was purchased from Sigma-Aldrich (St.
Louis, MO, USA). Cells were obtained directly from the
cell banks that perform cell line characterizations utiliz-
ing short tandem repeat profiling and passaged in the
authors’ laboratory for fewer than 6 months after resus-
citation. HEC-1-B cell line was maintained in MEM
(Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with 10% fetal bovine serum (FBS), Ishikawa cell
line was cultured in MEM (Thermo Fisher Scientific,
Waltham, MA, USA), supplemented with 5% FBS, KLE
was maintained in DMEM, and AN3CA was cultured
using EMEM (Thermo Fisher Scientific, Waltham, MA,
USA), supplemented with 10% FBS. All cell lines were
maintained with supplementation of 2% penicillin/
streptomycin and incubated in humidified chamber at
37 °C in 5% CO2 atmosphere.
miR-92a-LNA-inhibitor and scramble control
miR-92a-3p-LNA-inhibitor (LNA-i-miR-92a) and scram-
ble control (LNA-i-miR-NC) had full phosphorothioate
(PS) backbones, were designed and purchased from
Exiqon (Vedbaek, Denmark). LNA-i-miR-92a was cus-
tom designed to work effectively in human cells in vitro
and in mice xenograft of human EC and had a following
sequence: CGGGACAAGTGCAAT. LNA-i-miR-NC se-
quence was as follows ACGTCTATACGCCCA. Oligo-
nucleotides used for the in vitro study were FAM
labeled. The oligonucleotides were HPLC and Na salt
exchanged purity level and were delivered lyophilized.
The systemic effects of miR-92a-LNA-inhibitor could be
reliably evaluated in vivo, as sequences of human and
murine miR-92a-3p are identical.
Transfection
Oligonucleotides were incubated with Lipofectamine
RNAiMAX (Thermo Fisher Scientific, Waltham, MA,
USA) at concentration of 12 pmol after dilution in Opti-
MEM (Thermo Fisher Scientific, Waltham, MA, USA).
The mixture was added to cells and seeded into 16-wells
or 96-wells plate at a density of 2×104 cells per well de-
pending on experiment format. Successful transfection
(>50% of all cells) was confirmed by visual fluorescence
microscopic analysis.
Luciferase reporter experiments
In order to additionally evaluate transfection efficiency
and assess, if the studied inhibitor had a functional im-
pact within studied cell lines we co-transfected 1×106
EC cells with 50nM miR-205-LNA-inhibitor or scramble
control and 30 ng/μl of pLightSwitch_3′UTR reporter
vector containing optimized target sequence comple-
mentary to the miR-205-5p (based on miRBase 16)
cloned downstream of RenSP luciferase gene (Acitve
Motif, Carlsbad, CA, US). To evoke luciferase reporter
signal 24 h following the transfections 100 μg of Light-
Switch Assay reagent (Acitve Motif, Carlsbad, CA, US)
was added to wells and after 30 min of incubation in the
room temperature the luminescence was measured using
VictorX4 multimode plate reader (Perkin-Elmer,
Waltham, MA, USA). The experiments were performed
according to manufacture’s protocol. The empty
pLightSwitch_3′UTR reporter vector served a positive
transfection control and a negative control for micro-
RNA signaling. We also used pLightSwitch_Random 3′
UTR Control 1 as an additional negative control for
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microRNA signaling. All experiments were performed in
triplicates and repeated tree times.
RNA isolation
RNA isolation from fresh tissues stored in RNAlater
(Thermo Fisher Scientific, Waltham, MA, USA) and cell
lines was performed using mirVANATM miRNA Isola-
tion Kit (Thermo Fisher Scientific, Waltham, MA, USA)
according to manufacturer’s protocol. Forty milligrams
of macrodissected tissue was used for each isolation.
After extraction RNA underwent DNase treatment using
Turbo DNAase Kit (Thermo Fisher Scientific, Waltham,
MA, USA).
Before RNA isolation from FFPE tissues 10 μm sec-
tions containing at least 70% of cancer cells were pre-
pared by microdissection. RNA isolation from FFPE
specimens was performed using RecoverAll™ Total
Nucleic Acid Isolation Kit for FFPE Tissues (Thermo
Fisher Scientific, Waltham, MA, USA) according to the
protocol provided by the manufacturer. After extraction
RNA underwent DNase treatment using Turbo DNAase
Kit (Thermo Fisher Scientific, Waltham, MA, USA).
RNA quality control
RNA integrity was checked using Bioanalyzer 2100
(Agilent Technologies, Santa Clara, CA, USA) and
Agilent RNA Nano kit. RIN values of RNA ranged be-
tween 6 and 8.6. Only samples with RIN ≥ 6 were used
in downstream applications. Concentration and purity of
RNA were measured using spectrophotometry and Bio-
photometer with Hellma TrayCell (Eppendorf, Hamburg,
Germany). 260/280 ratio of all RNA samples ranged be-
tween 1.8 and 2.2. All samples were stored at −80 °C.
Reverse transcription and qPCR
Reverse transcription
Reverse transcription (RT) was performed using
TaqMan® MicroRNA Reverse Transcription Kit and spe-
cific primers (Thermo Fisher Scientific, Waltham, MA,
USA). RNA extracted from tissues was reverse tran-
scribed in 7.5 μl reactions. Each RT reaction consisted
of: 3.5 μL RT Master Mix (0.75 μL 10xRT Buffer,
0.075 μL 100 mM dNTPs, 0.5 μL Multiscribe Reverse
Transcriptase, 0.095 μL RNase Inhibitor (20U/μL),
2.08 μL Nuclease-free water), 1.5 μL of specific starters
and 5 ng RNA in 2.5 μL solution.
RT reactions were carried using following protocol: 16 °C
for 30 min, followed by 42 °C for 30 min and 85 °C for
5 min. All RT reactions were carried out in triplicates in
Mastercycler ep gradient S (Eppendorf, Hamburg,
Germany) and stored in −20 °C.
qPCR
qPCR was performed using single tube TaqMan® Micro-
RNA Assays and TaqMan® 2 × Universal PCR Master
Mix, No AmpErase® UNG (Thermo Fisher Scientific,
Waltham, MA, USA) in 10 μl reactions. For miRNA ex-
pression analysis in tissues each qPCR reaction consisted
of: 0.5 μL 20×TaqMan® MicroaRNA Assay (Thermo
Fisher Scientific, Waltham, MA, USA), 4.5 μL RT prod-
uct (dilution 1:15), 5 μL 2× TaqMan® 2× Universal PCR
Master Mix (Thermo Fisher Scientific, Waltham, MA,
USA).
All qPCR reactions were performed in duplicates in
ViiA7 Real–Time PCR System (Thermo Fisher Scien-
tific, Waltham, MA, USA) using protocol suggested by
manufacturer. Positive and negative control reactions as
well as inter–plate calibrator (IPC) reactions were car-
ried out on each plate. Raw qPCR data were initially
normalized with IPCs and adjusted for reaction effi-
ciency. Efficiencies of primer/probe sets were deter-
mined by performing standard qPCR with the six-fold
dilution of a pool of ten randomly chosen cDNA tem-
plates. Efficiencies for all amplicons were calculated
using the equation E = 10(−1/slope)-1.
For relative quantification of miRNA expression data
were normalized using geometric mean of expression of
experimentally chosen, stable endogenous controls
RNU48, RNU44, U75 and U6 which were previously ex-
perimentally validated [12].
xCELLigence real-time cells proliferation analysis
xCELLigence RTCA DP instrument (ACEA Biosciences
Inc., San Diego, CA, USA) was placed in the humidified
incubator at 37 °C and 5% CO2 atmosphere. Cell prolif-
eration experiments were carried out using E-plates ac-
cording to manufacturer protocol. Cells were seeded
into E-16 plate at a density 2×104 in 100ul per well and
experiment was running for 96 h. Each experiment was
performed in triplicate. Data was analyzed using RTCA
software and Slope was calculated every 12 h.
Cell proliferation assay
Proliferation was measured using Delfia cell proliferation
kit (Perkin-Elmer, Waltham, MA, USA) according to
manufacturer protocol. BrdU incorporation was measured
by time–resolved fluorescence 48 h after transfection
using VictorX4 multimode plate reader (Perkin-Elmer,
Waltham, MA, USA). All experiments were performed in
triplicates and repeated tree times.
Animals and in vivo study design
In vivo study was conducted in 15 female Cby.Cg-Foxn1
< nu>/cmdb mice aged 6 to 8 weeks with the body mass
between 16.3 and 20.2 g. The animals were purchased
from Centre of Experimental Medicine, Medical
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University of Białystok. The animals were housed in the
sterile conditions and were monitored every other day
for weight, physical activity and signs of distress. Ethical
Committee of Medical University of Białystok approved
study design and experimental procedures (# 7/2012).
EC xenografts were induced by subcutaneous injection
of 50 μl suspension of HEC-1-B cells in PBS (1×107
cells) into interscapular area. Mice were randomly di-
vided into three groups (five animals in each group) and
were treated with miR-205-LNA-inhibitor, scramble
control or PBS, respectively. MiR-92a-LNA-inhibitor
and scramble control were administered intraperitoneally
in the dose of 25 mg/kg three times per week. Injections
were commenced on the day following the HEC-1B cells
injection. The experiment was conducted for 32 days.
After the last injection, which took place on the 20 day of
the experiment the mice were left for observation and
they were sacrificed by anesthesia performed with 3% iso-
fluran. 0.5 mL of blood was retrieved from the heart of
each animal and was preserved in EDTA for blood count.
Tissues were collected and half of each organ was pre-
served for RNA isolation in RNA later and −80 °C, and
the other half for histology studies in buffered 10% forma-
lin, and processed to paraffin blocks. Four micrometre
slides were cut on the microtome and stained with
hematoxylin and eosin (H + E).
In vivo imaging
Near IR fluorescence imaging of live animals was per-
formed on the 15th experimental day using Odyssey
Infrared Imaging System (LI-COR Biotechnology,
Lincoln, NE, USA). Twenty-four hours before imaging
the animals were injected with the epidermal growth fac-
tor antibody – EGF-IRDye-800CW (LI-COR Biotechnol-
ogy, Lincoln, NE, USA), which was delivered via tail vein
in the dosage of 1 nmol/L per mice. The affinity of the
antibody to HEC-1B cells was assessed in the in vitro ex-
periment prior to in vivo imaging.
Statistical analysis
qPCR data processing and analysis was performed using
GenEx 5.3.4. (MultiD). After normalization data were
log transformed before statistical analysis. Results of
functional experiments are presented as means with
standard deviation (SD) of three independent experi-
ments performed in triplicates. Comparisons between
two groups were performed using Student’s t test with
or without Welch correction depending on the equality
of variances tested Fisher test. For comparisons between
dependent groups the paired t-test was utilized. For mul-
tiple comparisons of independent groups ANOVA test
with Tuckey-Kramer post-hoc test was applied. Statis-
tical tests were two-sided and statistical significance was
determined by p-value of less that 0.05. Statistical
analyses were performed using MedCalc Statistical Software
version 14.12.0 (MedCalc Software bvba, Ostend, Belgium;
http://www.medcalc.org; 2014).
Results
MiR–92a expression in endometrial cancer cells
Expression of miR–92a was significantly increased in
HEC-1-B (p = 0.013), Ishikawa (p = 0.008) and AN3CA
(p = 0.042) cells in comparison to normal endometrial
samples (Fig. 1).
Functional impact of miR-92a-LNA-inhibitor within studied
cell lines
In order to assess LNA-i-miR-92a activity in studied cell
lines and verify its potential to knock-down miR-92a-3p
pLightSwitch_3′UTR reporter vector containing opti-
mized target sequence complementary to the miR-92a-3p
was co-transfected with either miR-92a-LNA-inhibitor or
scramble control. Luciferase activity was significantly in-
creased 24 h after transfection proving that the inhibitor
was efficient, biologically available and functional within
the cells (Fig. 2).
MiR-92a inhibits proliferation of EC cells in vitro
To assess anti-proliferative activity induced by LNA-i-
miR-92a, we transfected HEC-1-B, Ishikawa and KLE
cells and monitored cells proliferation for 72 h using
xCELLigence technology. The xCELLigence system is a
label-free cell-based assay system, which uses culture
plates containing gold microelectrodes to non-invasively
monitor the viability of cultured cells. The electrical im-
pedance of the cell population in each well is measured
by electrodes what provides quantitative real-time infor-
mation about the cells’ condition. During the experiment
Fig. 1 MiR–92a-3p expression in EC cell lines in comparison to
normal endometrium (NE) tissues (n = 31); significant increase was
observed in case of HEC-1-B (p = 0.013), Ishikawa (p = 0.008),
AN3CA (p = 0.042)
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the impedance value of each well was automatically
monitored by the xCELLigence system for duration of
72 h. The rate of cell growth was determined by calcu-
lating the slope of the line between two given time
points. Negative Slope means that cell index decrease
with time and cells detach from wells bottom. Figure 3
presents the mean slope of three experiments performed
in triplicates calculated at six time points between 12
and 72 h after transfection.
The transfection of LNA-i-miR-92a resulted in a sig-
nificant inhibition of proliferation in HEC-1-B and KLE
cell lines as compared to LNA-i-miR-NC. Stronger and
earlier occurring effects were observed in KLE cells
comparing to HEC-1-B cells. The proliferation rate of
Ishikawa cells treated with LNA-i-miR-92a was lower,
when compared to LNA-i-miR-NC at 12 h., however
scramble control seemed to have more inhibitive effect
during subsequent time points. Nevertheless rate of pro-
liferation of Ishikawa cells was still significantly lower as
compared to untreated control (Fig. 3a–d).
In vivo effects of systemic administration of miR-92a-LNA-
inhibitor
Effects of intraperitoneal administration of miR-92a-
LNA-inhibitor were observed in experimental animals
for 32 days. During this time animals obtained nine dos-
ages of the inhibitor or LNA-i-miR-NC or PBS.
Significant inhibition of tumor growth as compared to
LNA-i-miR-NC was observed after second injection of
miR-92a-LNA-inhibitor and it was observed until the 12th
experimental day (after six dosages of miR-92a-LNA-in-
hibitor) (Fig. 4a).
In vivo imaging studies were performed on the 15th
day of experiment and were presented in Fig. 4b and
Additional file 1. No visible metastatic sites or extensive
infiltration were revealed in either group on scanning
Fig. 2 Specificity of LNA-i-miR-92a activity in HEC-1-B cells. The
difference was statistically significant p-value = 0.023
Fig. 3 Antiproliferative effect induced by transient transfection of LNA-i-miR-92a in endometrial cancer cell lines compared to scramble control
(LNA-i-miR-NC): a HEC-1-B, b Ishikawa, c KLE; d antiproliferative effect induced by transient transfection of LNA-i-miR-92a in Ishikawa cell lines
compared to untreated control (lipofectamine). Averaged values ± SD from three independent experiments performed in triplicates are presented.
* p-value <0.05
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tumor with Li-COR Odyssey Infrared Imaging Detection
System. Tumors retrieved from the animals at the end of
the experiment were presented in the Additional file 2.
MiR-92a-3p expression in mice tissues
At the end of the experiment miR-92a-3p expression was
measured in tumors and as well as in vital organs. The re-
sults were presented in Fig. 4c. After treatment with miR-
92a-LNA-inhibitor expression of miR-92a-3p was signifi-
cantly decreased in liver (p < 0.0001), and kidneys (p <
0.0001), and close to significant decrease was noted
in heart (p = 0.063). Conversely, increase of miR-92a-
3p expression was found in tumor tissues (p = 0.014).
Toxicity assessment of systemic administration of miR-
92a-LNA-inhibitor
During the whole experimental period all animals toler-
ated procedures well and behaved similarly as assessed
by activity level and food and water intake, which were
normal. Body weights did not differ between three
groups at the end of the experiment (Table 1). Measure-
ments of organs retrieved from animals revealed significant
increase of spleen and lungs in miR-92a-LNA-inhibitor
group in comparison to PBS and scramble control. No dif-
ferences were found in regards to weights of liver, kidneys,
brain, heart, uterus and ovaries (Table 1). Complete blood
counts were performed at the end of the experiment and
no significant differences were observed in miR-92a-LNA-
inhibitor treated animals in comparison to PBS or scramble
control. There were no significant differences between
scramble and PBS groups either (Table 2).
Histology studies
The microscopic examination of heart, spleen, pancreas,
lung and brain did not show any significant lesions in
Fig. 4 In vivo effects of systemic administration of miR-92a-LNA-inhibitor. a Subsequent measurements of tumor volume showed significant differences
between miR-92a-LNA-inhibitor, scramble control (LNA-i-miR-NC) and not treated animals (PBS), * vs. scramble - p-value < 0.05, # vs. PBS – p-value < 0.05;
b Because cancer cells over-express epidermal growth factor receptor, a non-invasive IR fluorescent-labeled probe for evaluating tumor size in vivo using
Li-COR Odyssey Infrared Imaging Detection System was utilized; scanning tumor images revealed markedly reduced fluorescence intensity in the inhibitor
group suggestive of an attenuating effect; in addition, no visible metastatic sites or extensive infiltration were revealed in either group – graph
of representative animals; c MiR–92a-3p expression in mice tissues - significant difference was observed in case of tumor (p = 0.027),
kidney (p < 0.0001), liver (p < 0.0001) and close to significant difference in heart (p = 0.063); bars represent Δ Cq log mean averaged
values ± SD; *p-value < 0.05
Torres et al. BMC Cancer  (2016) 16:822 Page 6 of 10
any of the animals. There was also no sign of metastatic
spread.
The microscopic examination of the liver samples
from three miR-92a-LNA-inhibitor treated animals re-
vealed changes in comparison to PBS and scramble con-
trol. The changes consisted of very small, discrete foci of
necrosis of small groups of hepatocytes scattered within
the lobules, that were accompanied by accumulation of
mononuclear inflammatory cells, signs of liver cells re-
generation including enlarged nuclei with prominent nu-
cleoli, bi- or trinucleated hepatocytes and scattered
mitotic figures. Single apoptotic cells, steatosis of single
hepatocytes and focal proliferation of Kupffer cells were
also observed (Fig. 5).
Discussion
MiR-92a belongs to a highly conserved family, which
arises from three paralog clusters miR-17-92, miR-106a-
363, and miR-106b-25. Mature miR-92a can arise from
an intronic miR-92a-1 located at chromosome 13q31-
q32 and from miR-92a-2 encoded on chromosome
Xq26.2. Deregulation of miR-92a was observed in
various malignant tumors and its aberrant expression
was related to promotion of tumor proliferation, inva-
sion and metastasis as well as inhibition of cancer cells
apoptosis [7]. However it was not connected with EC
pathogenesis until our recent finding of its up-regulation
in tissues and plasma of EC patients [3]. That observa-
tion was recently supported by the deep sequencing
study of Lu et al., who found that miR-92a expression
differed between Ishikawa and HEC-1-B lines, being in-
creased in the latter. The authors also reported the in-
consistent expression pattern of the miR-17-92 cluster
between the two EC cell lines, with non-homologous
miRNA species differentially regulated in those lines
[13].
Based on those results we hypothesized that miR-92a
exhibited pro-oncogenic properties in EC, and it could
be a targeted in a gene–specific therapy. LNA-modified-
oligonucleotides used in the presented study to knock-
down miR-92a inactivate their target microRNAs by
forming stable complexes with the targets, which are
then sequestered within the cell [10]. Due to their chem-
ical properties LNA-modified-oligonucleotides are stable
Table 1 Body weights and weights of organs collected from experimental animals
Organ
weight (g)
LNA-i-miR-92a LNA-i-miR-NC PBS P value
(1) (2) (3) 1 vs. 2 1 vs. 3 2 vs. 3
Mice weight 20.3 19.9 18.9 NS NS NS
Spleen 0.13 0.08 0.08 0.0005 0.004
Liver 1.20 1.13 1.19 NS NS
Kidney 0.34 0.3 0.32 NS NS
Heart 0.11 0.12 0.13 NS NS
Lungs 0.16 0.14 0.14 0.01 0.04
Brain 0.4 0.37 0.38 NS NS
Uterus 0.14 0.19 0.16 NS NS
Ovaries 0.04 0.04 0.04 NS NS
NS not significant
Table 2 Blood cell counts of experimental animals
Parameter LNA-i-miR-92a LNA-i-miR-NC PBS P value
(1) (2) (3) 1 vs. 2 1 vs. 3 2 vs. 3
Hb (g/dL) 11.7 13.2 12.7 NS NS NS
RBC (×106/mm3) 7.5 8.3 7.85
WBC (×103/mm3) 1.5 1.8 1.7
Ht (percent) 39.2 42.7 40.4
PLT (×109/L) 726 730 733
MCV (xm3) 52.4 51.2 51.7
MCH (pg/cell) 15.6 15.6 16.2
MCHC (g/dL) 30.5 30.7 31.5
NS not significant
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in body fluids what facilitates their systemic delivery.
Moreover, clinical trials indicated their clinical feasibility
and safety in humans [14, 15].
Only few articles presented similar attempts of
LNA-modified-oligonucleotides systemic delivery in
human cancer models. Therefore, treatment schedule
proposed in the presented study was developed based
on consultations with the manufacturer and on the
findings of Elmén et al., who reported that miR-
122:LNA–antimiR duplexes were stable in mouse
plasma over 96 h [10].
Increased expression of miR-92a in EC cell lines, as
compared to healthy endometrial tissues was observed,
what confirmed our previous results in human tissues
[3]. The biological effect following transfection of miR-
92a-LNA-inhibitor was confirmed in studied cell lines
and efficient transfection conditions were verified by in-
creased luciferase activity. Biological effect of miR-92a
knock-down was inspected by proliferation studies,
using xCELLigence real-time cells proliferation analysis,
which allowed monitoring of time-resolved changes in
EC proliferation.
LNA-i-miR-92a inhibited proliferation of HEC-1-B
and KLE cell lines as compared to LNA-i-miR-NC, and
the effect occurred earlier in KLE cells. Soon after trans-
fection the proliferation rate of Ishikawa cells treated
with LNA-i-miR-92a was lower when compared to
LNA-i-miR-NC, however scramble control seemed to
have more inhibitive effect during subsequent time
points. Nevertheless rate of proliferation of Ishikawa
cells was still significantly lower as compared to un-
treated control. The effect of non-targeting control was
quite large in all our experiments in all endometrial cell
lines, and therefore we speculate that this might have
been due the non-specific effect of the LNA-technology.
Based on the in vitro results we speculated that sys-
temic delivery of LNA-i-miR-92a could inhibit EC
xenograft tumor growth in vivo. We found that ad-
ministration of the inhibitor was feasible and was not
connected with significant toxic effects. Similar min-
imal toxicities were seen in a study, which utilized
miR-10b antagomirs in mice ovarian cancer xenograft
model [16]. Contrarily, Di Martino et al. who evalu-
ated effects of LNA-miR-221-inhibitor in the multiple
myeloma mice xenograft did no observe any acute or
chronic toxicities [17].
After intraperitoneal injection of 25 mg/kg LNA-i-
miR-92a three times per week a significant decrease in
tumor growth was observed until the 12th experimental
day. The last three dosages did not maintain the attenu-
ating effect on tumor growth. We speculated that such
phenomenon could be attributed to inefficient penetra-
tion of the inhibitor through the bulk of tumor tissue
with intraperitoneal administration. Our speculations are
supported by the study performed by Di Martino et al.,
who observed that intravenous administration of LNA-
inhibitor in multiple myeloma mice xenograft resulted in
more efficient inhibition of tumor growth in comparison
to intraperitoneal administration [17].
Fig. 5 Histological changes encountered after treatment with miR-
92a-LNA-inhibitor in mice liver; a PBS group - liver architecture
within normal limits; b LNA-i-miR-NC group - liver architecture
within normal limits; c LNA-i-miR-92a group - intralobular necrosis of
hepatocytes with scattered mononuclear inflammatory cells and
signs of hepatocytes regeneration with binucleated cells present;
slides stained with H + E × 400
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Extended observation of the animals after discontinu-
ation of treatment revealed marked acceleration of
tumor growth in LNA-i-miR-92a treated animals, sug-
gesting that the inhibitory effect of LNA-i-miR-92a
needs to be sustained by regular administration of the
inhibitor. Consistent with the final tumors measure-
ments were miR-92a expression studies in mice tissues,
which revealed its significantly higher levels in the tumor
tissues from LNA-i-miR-92a treated animals. We sus-
pect that such phenomenon could result from a rebound
effect of increased miR-92a synthesis after the period of
decreased availability during inhibitor treatment.
There are some limitations to our study, which we plan
to address in the future. Firstly, we were not able to evalu-
ate alternative root of inhibitor administration. Therefore it
needs to be confirmed if intravenous administration could
sustain the inhibitory effect on tumor growth. Secondly, the
phenomenon of accelerated tumor growth after treatment
discontinuation needs to be explained. As single miRNAs
regulate several various pathways chances are that inhib-
ition of mR-92a could adversely influence systemic or local
defensive mechanisms in tumour bearing mice. Thirdly, it
would be interesting to assess the dose dependent response
to LNA-i-miR-92a and finally the investigations of in vivo
response in xenograft derived from other endometrial can-
cer cells could be of interest, as it was proven in clinical
studies that endometrial cancer is a heterogeneous entity in
regards to response to anti-cancer treatment [18].
Conclusions
In conclusion, our study showed that LNA-i-miR-92a
was a potent inhibitor of EC growth in vitro. It also
demonstrated that systemic administration of LNA-i-
miR-92a was feasible and exerted moderate inhibitory
effect on endometrial cancer xenograft growth in vivo
with minimal toxic effects in treated animals. Taken to-
gether, these results indicate that systemic delivery of
miR-92a-LNA-modified-inhibitor could be a promising
treatment strategy for endometrial cancer and warrants
further studies investigating other routes of inhibitor de-
livery, possibly in other animal models.
Additional files
Additional file 1: Images of representative animals; scanning with
Li-COR Odyssey Infrared Imaging Detection System images revealed
markedly reduced fluorescence intensity within tumors in the inhibitor
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